Compugen Ltd. (NASDAQ: CGEN) today announced that the Company was invited to present at the Molecular Medicine Tri-Conference 2013, at Moscone Convention Center in San Francisco, California.
Dr. John Hunter, Vice President, Antibody Research & Development at Compugen, Inc., a wholly owned subsidiary of Compugen Ltd., will participate in a session entitled Cancer Biologics: Approaches Changing the Treatment of Cancer.
